Table 1.
Demographic and clinical characteristics of patients with RA pattern EIA
| Value | n missing (%) | |
|---|---|---|
| n = 7455 | ||
| Age, mean (s.d.) | 56.7 (16.1) | 0 |
| Female (%) | 4647 (62.3%) | 0 |
| IMD decile, mean (s.d.) | 5.4 (2.9) | 719 (9.6%) |
| BAME (%) | 987 (13.2%) | 0 |
| Paid work >20 h/week (%) | 3529 (48.0%) | 104 (1.4%) |
| Current smoker (%) | 1422 (19.1%) | 0 |
| ≥1 comorbidity (%) | 3000 (40.2%) | 100 (1.3%) |
| Seropositive (%) | 3779 (56.3%) | 742 (10.0%) |
| Symptom duration (%) | 68 (0.9%) | |
| <1 month | 637 (8.5%) | |
| 1–6 months | 4055 (54.4%) | |
| >6 months | 2695 (36.2%) | |
| Baseline DAS28, mean (s.d.) | 4.7 (1.5) | 677 (10.1%) |
| 3 months DAS28, mean (s.d.) | 3.3 (1.5) | 2,603 (34.9%) |
| 12 months DAS28, mean (s.d.) (n = 4273) | 2.8 (1.3) | 2902 (68.0%) |
| Primary care referral within 3 days (%) | 2908 (39%) | 107 (1.4%) |
| Rheumatology review within 21 days of referral (%) | 2977 (40%) | 51 (0.7%) |
| Commence therapy within 42 days of referral (%) | 3085 (41.4%) | 1746 (23.4%) |
| Baseline disease modifying therapy (%) | 257 (3.5%) | |
| No therapy | 2919 (39.1%) | |
| Monotherapy | 3556 (47.7%) | |
| Combination therapy | 723 (9.7%) | |
| Baseline corticosteroids (%) | 5151 (69.1%) | 206 (2.8%) |
Patients were considered seropositive if they had either RF or anti-citrullinated c-peptide antibodies.
BAME: black, Asian, and minority ethnic; DAS28: disease activity score; IMD: index of multiple deprivation.